Inspira Technologies Oxy B.H.N. Ltd. (IINNW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Inspira Technologies Oxy B.H.N. Ltd. (IINNW) operates as a specialty medical device entity focused on the research, development, manufacturing, and marketing of proprietary life support technologies designed for the treatment of acute respiratory failure within the Israeli market. The company specifically offers the INSPIRA ART100, a life support system utilized in procedural contexts to address critical respiratory needs. Although the specific sector and industry classifications are not publicly disclosed in available data, the company's operational focus on acute respiratory failure treatment situates it within the broader healthcare technology domain. The organization maintains a lean operational scale with a total workforce of 34 employees, reflecting a specialized rather than mass-market production approach. The company's financial profile indicates a very small market capitalization and annual revenue of $289,000, suggesting it operates as a micro-cap entity with limited financial resources relative to large-cap peers. These modest revenue figures and minimal employee count imply that the company is in an early-stage development or niche product phase, where survival and product validation are primary objectives rather than market dominance or profitability scaling.

वित्तीय स्वास्थ्य

The company reported a trailing twelve-month revenue of $289,000, yet it recorded a significant net income loss of $-13,220,000 and an EBITDA loss of $-13,473,000 during the same period. The substantial gap between the minimal revenue of $289,000 and the massive negative net income of $-13,220,000 reveals an extremely fragile cost structure where operating expenses far exceed income generation capabilities. Free cash flow stands at $-5,668,375, indicating that the company is burning through its cash reserves to fund operations and development without generating sufficient cash inflows to sustain itself independently. The gross margin is recorded at 0.7%, an exceptionally low figure that suggests high cost of goods sold relative to sales or significant unallocated production costs impacting the bottom line. The operating margin is listed at -4713.8%, and the profit margin is 0.0%, highlighting severe operational inefficiencies or one-time charges that have eroded profitability to a negative extreme. In terms of liquidity and leverage, the company holds $3.16M in cash against $480,000 in total debt, creating a net cash position that provides a temporary buffer against insolvency despite the earnings losses. The debt-to-equity ratio is 20.66, which is a high leverage metric, yet the substantial cash balance mitigates the immediate risk associated with this elevated ratio. The current ratio stands at 1.56, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the margin of safety is narrow given the ongoing cash burn rate. Return on Equity is -397.9% and return on assets is -127.0%, metrics that clearly demonstrate that management has not been effective in generating positive returns from shareholders' capital or the asset base during this reporting period.

मूल्यांकन आकलन

Trailing P/E and forward P/E ratios are unavailable for Inspira Technologies Oxy B.H.N. Ltd. due to the reported net losses and negative earnings trajectory, which precludes the calculation of standard earnings-based valuation multiples. The price-to-book ratio is 1.54, suggesting that the market values the company's equity at 1.54 times its book value, a premium that may reflect potential future product success or strategic assets not fully captured on the balance sheet. Price-to-sales and EV/EBITDA metrics are also not available, as the negative earnings and specific cash flow dynamics make these traditional valuation comparators inapplicable for this micro-cap entity. The stock has exhibited significant price volatility, trading between a 52-week high of $0.80 and a 52-week low of $0.05. The current trading price sits within this wide range, reflecting the speculative nature of the share price given the lack of profitability and the absence of established valuation benchmarks like P/E or EV/EBITDA. The beta value is 2.33, indicating that the stock's price volatility is more than twice that of the broader market, exposing investors to substantial price swings relative to systemic market movements. This high beta aligns with the company's status as a small-cap biotech or medical device firm, where price discovery is often driven by product milestones rather than current financial performance.

Growth & Income

Revenue growth and earnings growth rates are not available for comparison in the provided data, as the company has not yet achieved consistent profitability or reported year-over-year growth figures in its recent history. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of N/A, which means all available cash is currently directed toward sustaining operations and funding research rather than returning value to shareholders. This reinvestment strategy is typical for early-stage medical device companies that must prioritize product development and clinical validation over income distribution. The overall growth and income profile is characterized by a complete absence of income generation, with the company relying entirely on its $3.16M cash reserve to fund operations while it seeks to transition from a loss-making position to a profitable one. The lack of dividend history and the negative return metrics underscore that the investment thesis rests entirely on potential future operational turnaround rather than current financial returns or income streams.